A 78% response rate from a monotherapy in an unselected, all-comers KRAS G12C–mutant NSCLC population is a number that stops a room. For context, sotorasib and adagrasib — the two approved first-generation inhibitors — produced first-line ORRs in the 40–50% range in comparable settings. Elisrasib’s Phase I/II data presented at ASCO 2026 don’t just outperform those benchmarks; they do so without the PD-L1 stratification caveat that has complicated every immunotherapy-adjacent KRAS story to date.
The monotherapy cohort is the cleaner signal: 41 efficacy-evaluable patients, median follow-up of only 8.5 months, yet a median PFS of 12.4 months and a 12-month OS rate of 90.0%. Grade 3-or-higher treatment-related adverse events hit just 7%, with zero discontinuations and zero dose reductions. That tolerability profile matters clinically because it preserves combination flexibility — which D3 Bio is already exercising. The pembrolizumab arm posted an 81.3% ORR across all PD-L1 subgroups, with the high-expressers (TPS ≥50%) reaching 95.0%. The 12-month PFS rate of 53.7% in the combination cohort trails the monotherapy arm’s 50.8% only marginally, but the combination’s median follow-up is just 5.7 months, meaning durability data are still accumulating. Reading too much into that PFS comparison right now would be premature.
Two design features deserve scrutiny. First, the PD-L1-agnostic ORR consistency — 76.2% in TPS <1% patients on monotherapy — challenges the assumption that KRAS G12C inhibition needs immune co-activation to work in cold tumors. If that holds in larger cohorts, it rewrites first-line treatment algorithms for a mutation present in roughly 13% of lung adenocarcinomas. Second, preclinical CNS penetration data attached to elisrasib’s profile are not window-dressing; brain metastases are a persistent failure mode for KRAS inhibitors, and any intracranial activity signal in subsequent expansion cohorts would address an unmet need that neither sotorasib nor adagrasib has credibly solved.
The trial remains Phase I/II with the enrollment numbers that implies, and the survival curves are immature. The specific outcome that will define whether this molecule changes practice: whether D3 Bio’s announced Phase 3 randomized studies use PFS or OS as the primary endpoint, because regulators and payers will treat those two choices very differently when the registration package lands.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
